Press "Enter" to skip to content

Biogen Blasts Criticism of Alzheimer’s Drug as ‘Misinformation’

https://www.bloomberg.com/news/articles/2021-07-22/biogen-edges-up-revenue-forecast-as-earnings-beat-estimates
Biogen Inc. fought back against criticism of the unusual circumstances that led to the U.S. approval of its Alzheimer’s drug Aduhelm, saying in an open letter it has been the subject of “extensive misinformation and misunderstanding.”

More from BusinessMore posts in Business »
More from UncategorizedMore posts in Uncategorized »